Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of PFK-158 in Advanced Solid Malignancies
NCT02044861Phase 1Unknown
- Sponsor
- Advanced Cancer Therapeutics
- Start
- Mar 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PFK-158 in solid tumor, sponsored by Advanced Cancer Therapeutics. Primary endpoint: Maximum Tolerated Dose. Status: unknown.
02
Drugs
PFK-158
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02044861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044861.